Lack of rapid virological response predicts interferon-α2b/ribavirin therapy failure in HCV genotype 2 patients: A single-centre study

Maria Grazia Rumi, Alessio Aghemo, Roberta D'Ambrosio, Guido Ronchi, Ersilio Del Ninno, Silvano Gallus, Massimo Colombo

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: A minority of patients with HCV-2 chronic hepatitis does not attain a sustained virological response to interferon-based therapies. Registration trials have failed to identify the real proportion of HCV-2 non-responders, and predictors of non-response. The analysis of 'real-life' HCV-2 patients might help define the effectiveness of anti-HCV therapy and the role of response moderators. Methods: A re-analysis of all treatment-naive HCV-2 patients who consecutively received weight-dosed ribavirin with either 3 MU three times a week standard interferon-α2b or 1.5 μg/kg/week pegylated interferon-α2b. Results: The 94 interferon-treated patients and the 136 pegylated-interferon-treated patients were comparable for demography, prevalence of cirrhosis (25%) and adherence to therapy (74%). By intention-to-treat analysis, the overall sustained virological response rate was 80% (82% interferon versus 78% pegylated interferon). Overall, sustained virological rates were 83% for the 182 patients who cleared HCV RNA at week 4 (rapid virological response) and 52% for the 48 who did not (P

Original languageEnglish
Pages (from-to)1033-1040
Number of pages8
JournalAntiviral Therapy
Volume12
Issue number7
Publication statusPublished - 2007

Fingerprint

Ribavirin
Interferons
Genotype
Therapeutics
Intention to Treat Analysis
Chronic Hepatitis
Fibrosis
Demography
RNA
Weights and Measures

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{6e6b36abdec748fc9507f84f73eecd7a,
title = "Lack of rapid virological response predicts interferon-α2b/ribavirin therapy failure in HCV genotype 2 patients: A single-centre study",
abstract = "Background: A minority of patients with HCV-2 chronic hepatitis does not attain a sustained virological response to interferon-based therapies. Registration trials have failed to identify the real proportion of HCV-2 non-responders, and predictors of non-response. The analysis of 'real-life' HCV-2 patients might help define the effectiveness of anti-HCV therapy and the role of response moderators. Methods: A re-analysis of all treatment-naive HCV-2 patients who consecutively received weight-dosed ribavirin with either 3 MU three times a week standard interferon-α2b or 1.5 μg/kg/week pegylated interferon-α2b. Results: The 94 interferon-treated patients and the 136 pegylated-interferon-treated patients were comparable for demography, prevalence of cirrhosis (25{\%}) and adherence to therapy (74{\%}). By intention-to-treat analysis, the overall sustained virological response rate was 80{\%} (82{\%} interferon versus 78{\%} pegylated interferon). Overall, sustained virological rates were 83{\%} for the 182 patients who cleared HCV RNA at week 4 (rapid virological response) and 52{\%} for the 48 who did not (P",
author = "Rumi, {Maria Grazia} and Alessio Aghemo and Roberta D'Ambrosio and Guido Ronchi and {Del Ninno}, Ersilio and Silvano Gallus and Massimo Colombo",
year = "2007",
language = "English",
volume = "12",
pages = "1033--1040",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "7",

}

TY - JOUR

T1 - Lack of rapid virological response predicts interferon-α2b/ribavirin therapy failure in HCV genotype 2 patients

T2 - A single-centre study

AU - Rumi, Maria Grazia

AU - Aghemo, Alessio

AU - D'Ambrosio, Roberta

AU - Ronchi, Guido

AU - Del Ninno, Ersilio

AU - Gallus, Silvano

AU - Colombo, Massimo

PY - 2007

Y1 - 2007

N2 - Background: A minority of patients with HCV-2 chronic hepatitis does not attain a sustained virological response to interferon-based therapies. Registration trials have failed to identify the real proportion of HCV-2 non-responders, and predictors of non-response. The analysis of 'real-life' HCV-2 patients might help define the effectiveness of anti-HCV therapy and the role of response moderators. Methods: A re-analysis of all treatment-naive HCV-2 patients who consecutively received weight-dosed ribavirin with either 3 MU three times a week standard interferon-α2b or 1.5 μg/kg/week pegylated interferon-α2b. Results: The 94 interferon-treated patients and the 136 pegylated-interferon-treated patients were comparable for demography, prevalence of cirrhosis (25%) and adherence to therapy (74%). By intention-to-treat analysis, the overall sustained virological response rate was 80% (82% interferon versus 78% pegylated interferon). Overall, sustained virological rates were 83% for the 182 patients who cleared HCV RNA at week 4 (rapid virological response) and 52% for the 48 who did not (P

AB - Background: A minority of patients with HCV-2 chronic hepatitis does not attain a sustained virological response to interferon-based therapies. Registration trials have failed to identify the real proportion of HCV-2 non-responders, and predictors of non-response. The analysis of 'real-life' HCV-2 patients might help define the effectiveness of anti-HCV therapy and the role of response moderators. Methods: A re-analysis of all treatment-naive HCV-2 patients who consecutively received weight-dosed ribavirin with either 3 MU three times a week standard interferon-α2b or 1.5 μg/kg/week pegylated interferon-α2b. Results: The 94 interferon-treated patients and the 136 pegylated-interferon-treated patients were comparable for demography, prevalence of cirrhosis (25%) and adherence to therapy (74%). By intention-to-treat analysis, the overall sustained virological response rate was 80% (82% interferon versus 78% pegylated interferon). Overall, sustained virological rates were 83% for the 182 patients who cleared HCV RNA at week 4 (rapid virological response) and 52% for the 48 who did not (P

UR - http://www.scopus.com/inward/record.url?scp=36148981111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36148981111&partnerID=8YFLogxK

M3 - Article

C2 - 18018761

AN - SCOPUS:36148981111

VL - 12

SP - 1033

EP - 1040

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 7

ER -